|
Research sponsored by Pfizer shows patients receiving the company's blood pressure drug Norvasc had fewer cardiac problems than patients who received standard care.
In the 2-year of Amlodipine - Norvasc trial, 1,997 patients with coronary artery disease and normal or well-controlled hypertension received either Norvasc or placebo to compare the medicines' effectiveness in reducing major cardiovascular events. Eighty-five percent of the patients received treatment for high cholesterol and 20% of these patients had diabetes. Patients also received standard care which included aspirin, beta-blockers, other antihypertensive medications and statins.
Norvasc treated patients experienced 42% fewer hospitalizations for chest pain and 27% fewer coronary revascularization procedures, such as angioplasty and coronary artery bypass surgery, compared to patients receiving placebo.
The results of trial further confirm what has been shown in previous studies - that Norvasc provides cardiovascular benefits to patients with coronary artery disease in addition to effectively and safely reducing blood pressure levels.
|
